Drugs Monitor, Page 36

(19 May 2020) Lopinavir/Ritonavir- higher concentrations are required to reach the assumed EC50

May 20, 2020

Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) https://www.acpjournals.org/doi/10.7326/M20-1550 This reports the first pharmacokinetic data of lopinavir and ritonavir in patients hospitalized with COVID-19. Lopinavir trough levels were approximately 2-fold higher in COVID population than… Continue reading "(19 May 2020) Lopinavir/Ritonavir- higher concentrations are required to reach the assumed EC50"

(19 May 2020) Tocilizumab- may offer short-term survival benefit in severe ill patients

May 20, 2020

Off-Label Real World Experience Using Tocilizumab for Patients Hospitalized with COVID-19 Disease in a Regional Community Health System: A Case-Control Study https://doi.org/10.1101/2020.05.14.20099234 In an observational study, among 86 patients, 21 received Tocilizumab during the hospital stay. Both the Cox model… Continue reading "(19 May 2020) Tocilizumab- may offer short-term survival benefit in severe ill patients"

(19 May 2020) Interferon beta- no significant impact on in-hospital survival

May 20, 2020

CLINICAL EVALUATION OF IFN BETA1B IN COVID-19 PNEUMONIA: A RETROSPECTIVE STUDY https://doi.org/10.1101/2020.05.15.20084293 In this retrospective cohort study, 256 patients (106 patients in interferon group and 150 patients in control group) were analyzed. In the interferon group, more patients received hydroxychloroquine… Continue reading "(19 May 2020) Interferon beta- no significant impact on in-hospital survival"

(18 May 2020) Sarilumab- promising clinical benefit and good safety

May 19, 2020

Sarilumab use in severe SARS-CoV-2 pneumonia https://doi.org/10.1101/2020.05.14.20094144 In an observational clinical cohort study, of the 53 SARS-CoV-2 patients receiving Sarilumab, 39 (73.6%) were treated in medical wards (66.7% with a single infusion) while 14 (26.4%) in ICU (92.6% with a… Continue reading "(18 May 2020) Sarilumab- promising clinical benefit and good safety"

(18 May 2020) Hydroxychloroquine- effective in reducing the fatality of critically ill patients

May 19, 2020

Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19 https://link.springer.com/article/10.1007%2Fs11427-020-1732-2 In this retrospective study, 550 critically ill COVID-19 patients who need mechanical ventilation in Tongji Hospital, Wuhan were included. All 550 patients received comparable basic treatments including… Continue reading "(18 May 2020) Hydroxychloroquine- effective in reducing the fatality of critically ill patients"

(18 May 2020) Remdesivir- preliminary evidence of in-vivo virological effect

May 19, 2020

Early experience with remdesivir in SARS-CoV-2 pneumonia https://link.springer.com/article/10.1007/s15010-020-01448-x This case report describes an early experience with remdesivir in four critically ill COVID-19 patients admitted to the Monaldi Hospital, Naples, Italy. Patients received a 200 mg loading dose, followed by 100… Continue reading "(18 May 2020) Remdesivir- preliminary evidence of in-vivo virological effect"

(16 May 2020) Tocilizumab- Higher survival rate and outcome

May 18, 2020

Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration https://doi.org/10.1101/2020.05.13.20100081 A total of 94 patients with COVID-19 ARDS were analyzed. 44 were in the study group and 50 in the control group. Average HS score… Continue reading "(16 May 2020) Tocilizumab- Higher survival rate and outcome"

(16 May 2020) Hydroxychloroquine- no evidence for negative conversion of SARS-CoV-2

May 18, 2020

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial https://www.bmj.com/content/369/bmj.m1849 This study (conducted during the outbreak of covid-19 in China -ChiCTR2000029868) is the first randomised controlled trial evaluating administration of hydroxychloroquine in patients… Continue reading "(16 May 2020) Hydroxychloroquine- no evidence for negative conversion of SARS-CoV-2"

(16 May 2020) Anakinra- beneficial for treating severe COVID-19 patients with sHLH

May 18, 2020

FAVORABLE ANAKINRA RESPONSES IN SEVERE COVID-19 PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS https://doi.org/10.1016/j.chom.2020.05.007 This report comprises of data from the treatment of eight severe COVID-19 pneumonia patients– seven hospitalized in intensive care units (ICUs) in Greece and one non-ICU patient in… Continue reading "(16 May 2020) Anakinra- beneficial for treating severe COVID-19 patients with sHLH"

(16 May 2020) Arbidol-favorable clinical response when arbidol is combined with LPV/r

May 16, 2020

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. https://doi.org/10.1016/j.jinf.2020.03.002 In this retrospective cohort study, 16 patients received oral arbidol and LPV/r in the combination group and 17 received oral LPV/r only in… Continue reading "(16 May 2020) Arbidol-favorable clinical response when arbidol is combined with LPV/r"